Advanced Liver Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight's, "Advanced Liver Cancer Pipeline Insight" Report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced liver cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Advanced Liver Cancer Treatment Landscape. Click here to read more @ Advanced Liver Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Advanced Liver Cancer Pipeline Report

* In January 2025:- Hoffmann-La Roche:- This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
* In January 2025:-Tango Pharmaceuticals Inc.:- This is a Phase 1/2 multi-center, open label study in solid tumor patients who have a confirmed homozygous MTAP deletion in their tumor. The Phase 1 portion is a dose escalation study of oral TNG462 administered as a single agent and in combination with pembrolizumab in patients with confirmed MTAP-deleted solid tumors. In Phase 2, 6 expansion arms defined by confirmed MTAP-deleted tumor types will enroll in parallel at the RP2D(s) of TNG462 and in combination. In both parts of the study participants who tolerate the drug may continue treatment until disease progression.
* In January 2025:- AstraZeneca :- This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participaants with advanced unresectable HCC. Participants must not have received any prior systemic therapy for HCC. Participants may have previously received locoregional therapy (LRT) but must no longer be suitable for additional LRT. Any local treatment needs to have been completed at least 4 weeks prior to initiation of treatment. The study consists of 4 periods: screening (Day-28 to Day -1), Treatment period, safety follow-up and survival follow-up.
* In January 2025:- Polaris Group:- Safety will be evaluated by laboratory tests, vital sign measurements, physical examinations and subject medical history which will be performed to detect new abnormalities and any deterioration in pre-existing conditions. Efficacy will be determined by overall survival, progression free survival, pharmacodynamics (peripheral blood arginine and citrulline levels) and immunogenicity (antibodies to ADI-PEG 20).
* DelveInsight's Advanced Liver Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Liver Cancer treatment.
* The leading Advanced Liver Cancer Companies such as Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd. , and others.
* Promising Advanced Liver Cancer Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Parsaclisib, AV-299, Zimberelimab, Domvanalimab , and others.

Stay informed about the cutting-edge advancements in Advanced Liver Cancer treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Liver Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Liver Cancer Emerging Drugs Profile

* Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson's mechanism of action is mediated via deregulation of the NF-?B and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.

* ADI-PEG20: Polaris Pharmaceuticals

Pegylated arginine deiminase (ADI-PEG20) is a novel anticancer enzyme that produces depletion of arginine, which is a nonessential amino acid in humans. Certain tumors, such as malignant melanoma and hepatocellular carcinoma, are auxotrophic for arginine. These tumors that are sensitive to arginine depletion do not express argininosuccinate synthetase, a key enzyme in the synthesis of arginine from citrulline. ADI-PEG20 appears to show inhibitory effects on human melanomas and hepatocellular carcinomas. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.

* SRF388: Surface Oncology

SRF388 is a fully human IgG1 blocking antibody to IL-27 with potential to promote immune activation in the tumor microenvironment. The immunoregulatory cytokine IL-27 upregulates inhibitory immune checkpoint receptors (eg, PD-L1, TIGIT) and downregulates proinflammatory cytokines (eg, IFN?, TNFa). Currently, the drug is in the Phase II stage of development to treat Advanced liver cancer.

* TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. Currently, the drug is in the Phase I stage of development to treat Advanced liver cancer.

Learn more about Advanced Liver Cancer Drugs opportunities in our groundbreaking Advanced Liver Cancer Research and development projects @ Advanced Liver Cancer Unmet Needs [https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Liver Cancer Companies

Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd, and others.

Advanced liver cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Advanced Liver Cancer Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Discover the latest advancements in Advanced Liver Cancer treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Liver Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Advanced Liver Cancer Pipeline Report

* Coverage- Global
* Advanced Liver Cancer Companies- Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd. , and others.
* Advanced Liver Cancer Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Parsaclisib, AV-299, Zimberelimab, Domvanalimab, and others.
* Advanced Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Liver Cancer Pipeline on our website @ Advanced Liver Cancer Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Advanced liver cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced liver cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Namodenoson: Can-Fite BioPharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Product Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced liver cancer Key Companies
* Advanced liver cancer Key Products
* Advanced liver cancer- Unmet Needs
* Advanced liver cancer- Market Drivers and Barriers
* Advanced liver cancer- Future Perspectives and Conclusion
* Advanced liver cancer Analyst Views
* Advanced liver cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-liver-cancer-fda-approvals-clinical-trials-assessment-pipeline-insights-and-companies-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/nk-cell-therapy-market



This release was published on openPR.